Pharmaceuticals, Biotechnology and Life Sciences
Catabis expects top-line results in Q4 2020 from fully enrolled edasalonexent global phase 3 PolarisDMD trial in duchenne muscular dystrophy.
PhaseBio reported a net loss of $14.9 million for the three months ended March 31, 2020, which compared with a net loss of $7.3 million for the same period in 2019, which resulted in a net loss of $0.52.
Moderna has received FDA’s fast track designation for mRNA-1273 vaccine against the novel coronavirus, with finalizing protocol for Phase 3 study of mRNA-1273, expected to begin in early summer of 2020.
FARGO, N.D.–(BUSINESS WIRE)–#Aldevron–Aldevron, the leading plasmid DNA manufacturing company, has expanded its leadership team by appointing Dr. James Brown President…
DENVER–(BUSINESS WIRE)–ClinOne is expanding its strategic collaboration with BioIntelliSense to combine continuous health monitoring and clinical intelligence with the ClinOne…
Pfizer invites investors and the general public to listen to a webcast of a discussion with Charles Triano, Senior Vice President, Investor Relations
Cooley lawyers working in the technology and life sciences industries have been advising some of the world’s most innovative companies as they seek to deliver products and services to battle myriad aspects of the COVID-19 pandemic.
Ocular Therapeutix has dosed the first patient in phase 1 clinical trial of OTX-CSI for the treatment of dry eye…
Industry leaders connecting patient advocacy organizations in virtual approach ROCHESTER, N.Y. & PRINCETON, N.J.–(BUSINESS WIRE)–$BMY #AdvocacyExchange–In light of the COVID-19…
Te U.S. Food and Drug Administration (FDA) approved the myChoice CDx test for use as a companion diagnostic by healthcare professionals to identify certaikn advanced ovarian cancer patients.